Showing posts with label BMS-582664. Show all posts
Showing posts with label BMS-582664. Show all posts
Sunday, June 12, 2011
multinational study: Brivanib -oral- (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT)-- ASCO Meeting Abstract
Background:
Brivanib (B) is an oral once daily selective dual inhibitor of FGF and VEGF signaling currently in phase III development for advanced hepatocellular carcinoma and colorectal cancer.
"Biomarker exploration with potential for enrichment continues; breast and ovarian cohorts have been added to the trial."
add your opinions
BMS-582664
,
Brivanib
Subscribe to:
Posts
(
Atom
)